GLP-1 weight loss medications tied to higher rates of nail and hair issues
A multinational study compared 575 people using GLP-1 medications with people who had never taken them. It found 39% of users reported nail detachment versus 9% of non-users, and 66% reported at least one nail disorder. The researchers concluded that weight loss alone does not fully account for the higher rates.
The study compared 575 GLP-1 users with 1,329 people who had type 2 diabetes, obesity, or both but had never taken these drugs. Participants came from France, the United States, Brazil, and Mexico. Among users, 66% reported one or more nail conditions, versus 53% of controls; discoloration affected 46% versus 17%.
The research was presented at the EADV Congress 2026 and described as the first controlled investigation of this possible link. GLP-1 drugs act on hormone signals involved in appetite and blood sugar. Even among participants who lost weight, users still reported more nail problems, suggesting weight change alone does not explain the pattern. The report also links the drugs to hair loss and scalp inflammation.
The findings may prompt patients and clinicians to watch for nail, hair, and scalp changes during GLP-1 treatment. Because these drugs are widely used, even uncommon side effects could affect many people, potentially influencing treatment decisions, adherence, or dermatologic care. However, the study shows association, not causation, so impact may depend on further research and how risks are communicated.